



## Metal-organic frameworks for efficient drug adsorption and delivery

Kornelia Hyjek<sup>(1)</sup>✉, Przemysław Jodłowski <sup>(1)</sup>



<sup>(1)</sup> Faculty of Chemical Engineering and Technology, Cracow University of Technology, 31-155 Kraków, Poland



✉ Correspondence to: [kornelia.hyjek@doktorant.pk.edu.pl](mailto:kornelia.hyjek@doktorant.pk.edu.pl)




## 1. Anticancer drugs.


### 1.1. Drug Delivery System.



Table No.S1. Examples of anticancer drug delivery by metal-organic frameworks.



API	CAS number	Molar weight [ $\frac{g}{mol}$ ]	Molecular formula	Structural formula	Metal-Organic Framework	Applications	Literature
<b>5-fluorouracil (5-FU)</b>	51-21-8	130.078	C <sub>4</sub> H <sub>3</sub> FN <sub>2</sub> O <sub>2</sub>		MIL-100 (Fe) HKUST-1 FOLA@NH <sub>2</sub> -Eu:TMU-62 Zn-cpon-1 MOF-In1 MOF-In2 Fe-MIL53-NH <sub>2</sub> MIL-88 (Al) TDL-Mg MBM (Fe-MOF) MUT-2 [Dy <sub>2</sub> (L) <sub>2</sub> (H <sub>2</sub> O) <sub>2</sub> ] <sub>n</sub> UiO-66 Cu-MOF ZIF-90 ZIF-8	Tumors of the gastrointestinal tract	[1,2,10–13,3–9,9]
<b>Sodium dichloroacetate (DCA)</b>	2156-56-1	150.92	C <sub>2</sub> HCl <sub>2</sub> NaO <sub>2</sub>		CAU-7 Zr-fum (UiO66) Folic acid coated-UiO66 UiO-66	Cancers of the breast, lung and brain	[14–18]



<p><b><math>\alpha</math>-Cyano-4-hydroxycinnamic acid (<math>\alpha</math>-CHC)</b></p>	<p>54673-07-3</p>	<p>189.17</p>	<p><math>C_{10}H_7NO_3</math></p>		<p>CAU-7 Folic acid coated-UiO66 UiO-66</p>		<p>[18,19]</p>
<p><b>Curcumin (CUR)</b></p>	<p>458-37-7</p>	<p>368.39</p>	<p><math>C_{21}H_{20}O_6</math></p>		<p>Zr-DTBA</p>	<p>Cancers of the skin, lung, gastrointestinal tract, head and neck, bladder, prostate, breast, cervix</p>	<p>[20-27]</p>

<b>Doxorubicin (DOX)</b>	23214-92-8	543.52	$C_{27}H_{29}NO_{11}$		IR-MOF-3 MIL-53 (Fe) MIL-100 (Fe) NH <sub>2</sub> -UiO-66 MIL-100 (Al) DUT-32 ZIF-90	Cancers of the stomach, pancreas, prostate, testis, liver, kidney and cervix	[17,21,36-41,28-35]
<b>Busulfan</b>	55-98-1	246.30	$C_6H_{14}O_6S_2$		MIL-53(Fe) MIL-88A (Fe) MIL-89 (Fe) MIL-100 (Fe)	Cancers of the bone marrow and gastrointestinal tract	[42]
<b>Oridonin (ORI)</b>	28957-04-2	364.43	$C_{20}H_{28}O_6$		MIL-53 (Fe)	Cancers of the breast, thyroid	[43,43,44]


<b>Irinotecan</b>	97682-44-5	586.68	$C_{33}H_{38}N_4O_6$	 <p>The image shows the chemical structure of Irinotecan, a topoisomerase II inhibitor. It consists of a tropane bicyclic core (8-methyl-8-azabicyclo[3.2.1]octane) linked via an ester bond to a piperazine ring. This piperazine ring is further connected to a pyridine ring, which is substituted with a methyl group and a butyrate ester group. The butyrate group is attached to a pyrimidine ring, which is substituted with a methyl group and a butyrate ester group. The butyrate group is attached to a pyrimidine ring, which is substituted with a methyl group and a butyrate ester group. The butyrate group is attached to a pyrimidine ring, which is substituted with a methyl group and a butyrate ester group.</p>	MIL-88A (Fe)	Cancer of the colon and large intestine	[45]
-------------------	------------	--------	----------------------	---	--------------	---	------



<b>Floxuridine</b>	50-91-9	246.20	$C_9H_{11}FN_2O_5$		MIL-88A (Fe)	Colorectal cancer	[46]
<b>Gemcitabine monophosphate (gemcitabine)</b>	103882-84-4	263.20	$C_9H_{11}F_2N_3O_4$		MIL-100 (Fe)	Cancer of the lung, breast, ovary and bladder	[25,28,49–56,29,29,31,34,35,45,47,48]

<b>Topotecan</b>	123948-87-8	421.45	$C_{23}H_{23}N_3O_5$		MIL-100 (Fe)	Ovarian and lung cancer	[2,56,56–60]
<b>Cis-platinum</b>	15663-27-1	300.05	$PtCl_2(NH_3)_2$		Fe-MIL-101 UiO-66 UiO-66-NH <sub>2</sub>	Cancer of the testicles, lungs, bladder, ovary, cervix, head and neck	[17,28,65,66,29,31,34,61,61–64]

<p><b>Docetaxel (DTX)</b></p>	<p>114977-28-5</p>	<p>807.88</p>	<p><math>C_{43}H_{53}NO_{14}</math></p>		<p>Fe-BTC-3(H<sub>2</sub>O)<sub>4</sub> MIL-100 (Fe)</p>	<p>Cancer of the breast and urethra</p>	<p>[67]</p>
<p><b>Gallic acid (GA)</b></p>	<p>149-91-7</p>	<p>170.12</p>	<p><math>C_7H_6O_5</math></p>		<p>Cu-GA (NMOF)</p>	<p>Prostate cancer</p>	<p>[33,68–71]</p>



<b>Paclitaxel (PTX)</b>	33069-62-4	853.91	$C_{47}H_{51}NO_{14}$		Fe-BTC (Basolite®F300)	Cancers of the ovary, lung, head and neck	[31,72,73]
-----------------------------	------------	--------	-----------------------	---	------------------------	---	------------

<b>Siramesin (Sira)</b>	147817-50-3	454.589	$C_{30}H_{31}FN_2O$		ZIF-8	CNS-acting drug with anticancer potential	[74]
<b>Disulfiram (DSF)</b>	97-77-8	296.54	$C_{10}H_{20}N_2S_4$		Cu-MOF	Lung and prostate cancer	[29,75]
<b>Pyrrolidine dithiocarbamate gold(III) complex [(PDTCAu(III)Cl<sub>2</sub>)]</b>	-	-	-	-	ZnBTCA	Ovarian cancer	[63]



## 1.2. Drugs adsorption.

Table No.S2. Metal-organic frameworks for drug adsorption.

Drug	MOF	Adsorption efficiency [ $\frac{mg}{g}$ ]	Literature
<b>Curcumin (CUR)</b>	UiO-66-NH <sub>2</sub> functionalized with glycidyl methacrylate (UiO-66-GMA) and UiO-66-NH <sub>2</sub> functionalized with ethylenediamine (UiO-66-EDA)	423.85 (for UiO-66-EDA) 384 (for UiO-66-GMA) 364 (for UiO-66-NH <sub>2</sub> )	[27], [23]
<b>Methotrexate (MTX)*</b>	UiO-66-NH <sub>2</sub> functionalized with glycidyl methacrylate (UiO-66-GMA) and UiO-66-NH <sub>2</sub> functionalized with ethylenediamine (UiO-66-EDA) MIL-53 NH <sub>2</sub> -MIL-53 NH <sub>2</sub> -MIL-101	570.78 (for UiO-66-EDA) 450 (for UiO-66-GMA) 401 (for UiO-66-NH <sub>2</sub> ) 374.97 (for MIL-53) 387.82 (for NH <sub>2</sub> -MIL-53) 457.69 (for NH <sub>2</sub> -MIL-101)	[27], [76]
<b>Amoxicillin (AMX)*</b>	DUT-32 MIL-53 (Al)	- 758.5	[77] [78]
<b>5-fluorouracil (5-FU)</b>	ZIF-8	477	[79]
<b>Ibuprofen (IBP)</b>	PCDM-1000 ZIF-8 ATP@ZIF-8-DETA	320 (for PCDM-1000) 29 (for ZIF-8) 218.34 (for ATP@ZIF-8-DETA)	[80], [81]
<b>Diclofenac (DCF)</b>	PCDM-1000 ZIF-8	-	[80]
<b>Aspirin (ASA)</b>	ATP@ZIF-8-DETA UiO-66	350.88 (for ATP@ZIF-8-DETA) 140 (for MIL-127)	[81]

	UiO-66-NH <sub>2</sub> MIL-127		
<b>Ciprofloxacin (CIP)</b>	Fe <sub>3</sub> O <sub>4</sub> /HKUST-1	538	[82]
<b>Norfloxacin (NOR)</b>	Fe <sub>3</sub> O <sub>4</sub> /HKUST-1	513	[82]



Table No.S3. Examples of oncology drugs adsorbed by MOF materials.





API	CAS number	Molar weight [ $\frac{g}{mol}$ ]	Molecular formula	Structural formula	Applications	Literature
<b>Metotrexat (MTX)*</b>	59-05-2	454.44	C <sub>20</sub> H <sub>22</sub> N <sub>8</sub> O <sub>5</sub>		Ovarian cancer, lung cancer, leukemia, sarcomas	[23,27]
<b>Amoxicillin (AMX)*</b>	26787-78-0	365.40	C <sub>16</sub> H <sub>19</sub> N <sub>3</sub> O <sub>5</sub> S		-	[77,78]


## 2. Psychoactive substances.

### 2.1. Psychoactive substances adsorbents (*Antidotal Agents*).

Table No.S4. Metal-organic frameworks for psychoactive substances adsorptions.

Psychoactive substances	CAS number	Molar weight [ $\frac{g}{mol}$ ]	Molecular formula	Structural formula	Metal Organic Framework	Literature
<b>Methamphetamine</b>	537-46-2	149.23	C <sub>10</sub> H <sub>15</sub> N		ZIF-8 HKUST-1	[83], [84]
<b>Amphetamine</b>	300-62-9	135.21	C <sub>9</sub> H <sub>13</sub> N		Fe <sub>3</sub> O <sub>4</sub> /GO/ZIF-8 HKUST-1	[85], [84]

<b>Pseudoephedrine (PEP)</b>	90-82-4	165.23	$C_{10}H_{15}NO$		HKUST-1	[84]
<b>Cocaine (COC)</b>	50-36-2	303.35	$C_{17}H_{21}NO_4$		HKUST-1	[84]
<b>Tetrahydrocannabinol (THC)</b>	1972-08-3	314.46	$C_{21}H_{30}O_2$		Symulacja komputerowa różnych typów MOF	[86]
<b>Benzodiazepines (bromazepam, triazolam and diazepam)</b>	1812-30-2 28911-01-5 439-14-5	316.15 343.21 284.74	$C_{14}H_{10}BrN_3O$ $C_{17}H_{12}Cl_2N_4$ $C_{16}H_{13}ClN_2O$		MOF-808-SiO <sub>2</sub>	[87]

				 <p>The image shows the chemical structure of 5-chloro-L-tryptophan. It consists of an indole ring system attached to a tryptophan side chain. The indole ring has a chlorine atom (Cl) at the 5-position. The tryptophan side chain includes a methylene group, an alpha-carbon with a hydrogen atom, and a beta-carbon with a carboxyl group (COOH). The carboxyl group is shown with a red oxygen atom and a white hydrogen atom. The chlorine atom is shown in green. The structure is drawn in a skeletal format with explicit hydrogen atoms and a chlorine atom.</p>		
--	--	--	--	--	--	--

MOFs have also found use as a detection agents. The literature describes examples of the use of MOFs for the detection of Amphetamine-type stimulants (ATS), more specifically, the detection of 3-phenylpropylamine (3-PPA) has been demonstrated [88].

## References

- [1] Pooresmaeil, M.; Asl, E.A.; Namazi, H. A New PH-Sensitive CS/Zn-MOF@GO Ternary Hybrid Compound as a Biofriendly and Implantable Platform for Prolonged 5-Fluorouracil Delivery to Human Breast Cancer Cells. *J. Alloys Compd.* **2021**, *885*, 160992, doi:10.1016/j.jallcom.2021.160992.
- [2] Sethy, C.; Kundu, C.N. 5-Fluorouracil ( 5-FU ) Resistance and the New Strategy to Enhance the Sensitivity against Cancer : Implication of DNA Repair Inhibition. *Biomed. Pharmacother.* **2021**, *137*, 111285, doi:10.1016/j.biopha.2021.111285.
- [3] Hu, Z.; Qiao, C.; Xia, Z.; Li, F.; Han, J.; Wei, Q.; Yang, Q.; Xie, G.; Chen, S.; Gao, S. A Luminescent Mg-Metal-Organic Framework for Sustained Release of 5-Fluorouracil: Appropriate Host-Guest Interaction and Satisfied Acid-Base Resistance. *ACS Appl. Mater. Interfaces* **2020**, *12*, 14914–14923, doi:10.1021/acsami.0c01198.
- [4] Zorrilla-Veloz, R.I.; Stelzer, T.; López-Mejías, V. Measurement and Correlation of the Solubility of 5-Fluorouracil in Pure and Binary Solvents. *J. Chem. Eng. Data* **2018**, *63*, 3809–3817, doi:10.1021/acs.jced.8b00425.
- [5] Javanbakht, S.; Hemmati, A.; Namazi, H.; Heydari, A. Carboxymethylcellulose-Coated 5-Fluorouracil@MOF-5 Nano-Hybrid as a Bio-Nanocomposite Carrier for the Anticancer Oral Delivery. *Int. J. Biol. Macromol.* **2020**, *155*, 876–882, doi:10.1016/j.ijbiomac.2019.12.007.
- [6] Liu, F.J.; Xu, B.M. A Three-Dimensional DyIII-Based Metal-Organic Framework: Smart Drug Carrier and Anti-Lung Cancer Activity. *Zeitschrift fur Anorg. und Allg. Chemie* **2018**, *644*, 821–826, doi:10.1002/zaac.201800136.
- [7] Nazari, M.; Rubio-Martinez, M.; Tobias, G.; Barrio, J.P.; Babarao, R.; Nazari, F.; Konstas, K.; Muir, B.W.; Collins, S.F.; Hill, A.J.; et al. Metal-Organic-Framework-Coated Optical Fibers as Light-Triggered Drug Delivery Vehicles. *Adv. Funct. Mater.* **2016**, *26*, 3244–3249, doi:10.1002/adfm.201505260.
- [8] Souza, B.E.; Donà, L.; Titov, K.; Bruzzese, P.; Zeng, Z.; Zhang, Y.; Babal, A.S.; Möslein, A.F.; Frogley, M.D.; Wolna, M.; et al. Elucidating the Drug Release from Metal-Organic Framework Nanocomposites via in Situ Synchrotron Microspectroscopy and Theoretical Modeling. *ACS Appl. Mater. Interfaces* **2020**, *12*, 5147–5156, doi:10.1021/acsami.9b21321.
- [9] Akbar, M.U.; Badar, M.; Zaheer, M. Programmable Drug Release from a Dual-Stimuli Responsive Magnetic Metal-Organic Framework. *ACS Omega* **2022**, *7*, 32588–32598, doi:10.1021/acsomega.2c04144.
- [10] Xing, K.; Fan, R.; Wang, F.; Nie, H.; Du, X.; Gai, S.; Wang, P.; Yang, Y. Dual-Stimulus-Triggered Programmable Drug Release and Luminescent Ratiometric PH Sensing from Chemically Stable Biocompatible Zinc Metal-Organic Framework. *ACS Appl. Mater. Interfaces* **2018**, *10*, 22746–22756, doi:10.1021/acsami.8b06270.
- [11] Zhang, F.M.; Dong, H.; Zhang, X.; Sun, X.J.; Liu, M.; Yang, D.D.; Liu, X.; Wei, J.Z.



- Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs. *ACS Appl. Mater. Interfaces* **2017**, *9*, 27332–27337, doi:10.1021/acsami.7b08451.
- [12] Karimi Alavijeh, R.; Akhbari, K.; Tylianakis, E.; Froudakis, G.E.; White, J.M. Two-Fold Homointerpenetrated Metal-Organic Framework with the Potential for Anticancer Drug Loading Using Computational Simulations. *Cryst. Growth Des.* **2021**, doi:10.1021/acs.cgd.1c00868.
- [13] Gao, X.; Zhai, M.; Guan, W.; Liu, J.; Liu, Z.; Damirin, A. Controllable Synthesis of a Smart Multifunctional Nanoscale Metal-Organic Framework for Magnetic Resonance/Optical Imaging and Targeted Drug Delivery. *ACS Appl. Mater. Interfaces* **2017**, *9*, 3455–3462, doi:10.1021/acsami.6b14795.
- [14] Ferretti, V.; Bergamini, P.; Marvelli, L.; Hushcha, Y.; Gemmo, C.; Gambari, R.; Lampronti, I. Inorganica Chimica Acta Synthesis and Characterization of Pt Complexes Containing Dichloroacetate ( DCA ), Designed for Dual Anticancer Action. *Inorganica Chim. Acta* **2018**, *470*, 119–127, doi:10.1016/j.ica.2017.04.048.
- [15] Tataranni, T.; Piccoli, C. Review Article Dichloroacetate ( DCA ) and Cancer : An Overview towards Clinical Applications. **2019**, *2019*.
- [16] Abánades Lázaro, I.; Haddad, S.; Rodrigo-Muñoz, J.M.; Marshall, R.J.; Sastre, B.; Del Pozo, V.; Fairen-Jimenez, D.; Forgan, R.S. Surface-Functionalization of Zr-Fumarate MOF for Selective Cytotoxicity and Immune System Compatibility in Nanoscale Drug Delivery. *ACS Appl. Mater. Interfaces* **2018**, *10*, 31146–31157, doi:10.1021/acsami.8b11652.
- [17] Abánades Lázaro, I.; Haddad, S.; Rodrigo-Muñoz, J.M.; Orellana-Tavra, C.; Del Pozo, V.; Fairen-Jimenez, D.; Forgan, R.S. Mechanistic Investigation into the Selective Anticancer Cytotoxicity and Immune System Response of Surface-Functionalized, Dichloroacetate-Loaded, UiO-66 Nanoparticles. *ACS Appl. Mater. Interfaces* **2018**, *10*, 5255–5268, doi:10.1021/acsami.7b17756.
- [18] Orellana-Tavra, C.; Köppen, M.; Li, A.; Stock, N.; Fairen-Jimenez, D. Biocompatible, Crystalline, and Amorphous Bismuth-Based Metal-Organic Frameworks for Drug Delivery. *ACS Appl. Mater. Interfaces* **2020**, *12*, 5633–5641, doi:10.1021/acsami.9b21692.
- [19] Zhang, L.; Li, Y.; Yuan, S.; Zhang, S.; Zheng, H.; Liu, J. Bioactivity Focus of  $\alpha$ -Cyano-4-Hydroxycinnamic Acid ( CHCA ) Leads to Effective Multifunctional Aldose Reductase Inhibitors. **2016**, 1–13, doi:10.1038/pj.2016.37.
- [20] Alves, R.C.; Schulte, Z.M.; Luiz, M.T.; Bento Da Silva, P.; Frem, R.C.G.; Rosi, N.L.; Chorilli, M. Breast Cancer Targeting of a Drug Delivery System through Postsynthetic Modification of Curcumin@N3-Bio-MOF-100 via Click Chemistry. *Inorg. Chem.* **2021**, *60*, 11739–11744, doi:10.1021/acs.inorgchem.1c00538.
- [21] Lawson, S.; Rownaghi, A.A.; Rezaei, F. Combined Ibuprofen and Curcumin Delivery Using Mg-MOF-74 as a Single Nanocarrier. *ACS Appl. Bio Mater.* **2022**, *5*, 265–271, doi:10.1021/acsabm.1c01067.
- [22] Karimi Alavijeh, R.; Akhbari, K. Biocompatible MIL-101(Fe) as a Smart Carrier with High Loading Potential and Sustained Release of Curcumin. *Inorg. Chem.* **2020**, *59*, 3570–3578, doi:10.1021/acs.inorgchem.9b02756.
- [23] Molavi, H.; Zamani, M.; Aghajanzadeh, M.; Kheiri Manjili, H.; Danafar, H.; Shojaei, A.

- Evaluation of UiO-66 Metal Organic Framework as an Effective Sorbent for Curcumin's Overdose. *Appl. Organomet. Chem.* **2018**, *32*, 1–10, doi:10.1002/aoc.4221.
- [24] Zhong, T.; Li, D.; Li, C.; Zhang, Z.; Wang, G. Turn-on Fluorescent Sensor Based on Curcumin@MOF-5 for the Sensitive Detection of Al(3). *Anal. Methods* **2022**, *14*, 2714–2722, doi:10.1039/d2ay00849a.
- [25] Yin, D.; Hu, X.; Cai, M.; Wang, K.; Peng, H.; Bai, J.; Xv, Y.; Fu, T.; Dong, X.; Ni, J.; et al. Preparation, Characterization, and In Vitro Release of Curcumin-Loaded IRMOF-10 Nanoparticles and Investigation of Their Pro-Apoptotic Effects on Human Hepatoma HepG2 Cells. *Molecules* **2022**, *27*, doi:10.3390/molecules27123940.
- [26] Lei, B.; Wang, M.; Jiang, Z.; Qi, W.; Su, R.; He, Z. Constructing Redox-Responsive Metal-Organic Framework Nanocarriers for Anticancer Drug Delivery. *ACS Appl. Mater. Interfaces* **2018**, *10*, 16698–16706, doi:10.1021/acsami.7b19693.
- [27] Molavi, H.; Moghimi, H.; Taheri, R.A. Zr-Based MOFs with High Drug Loading for Adsorption Removal of Anti-Cancer Drugs: A Potential Drug Storage. *Appl. Organomet. Chem.* **2020**, *34*, 4–9, doi:10.1002/aoc.5549.
- [28] Lawson, H.D.; Walton, S.P.; Chan, C. Metal – Organic Frameworks for Drug Delivery: A Design Perspective. **2021**, doi:10.1021/acsami.1c01089.
- [29] Lawson, H.D.; Walton, S.P.; Chan, C. Metal-Organic Frameworks for Drug Delivery: A Design Perspective. *ACS Appl. Mater. Interfaces* **2021**, *13*, 7004–7020, doi:10.1021/acsami.1c01089.
- [30] Maranescu, B.; Visa, A. Applications of Metal-Organic Frameworks as Drug Delivery Systems. *Int. J. Mol. Sci.* **2022**, *23*, doi:10.3390/ijms23084458.
- [31] Osterrieth, J.W.M.; Fairen-jimenez, D. Metal – Organic Framework Composites for Theragnostics and Drug Delivery Applications. **2020**, *2000005*, 1–14, doi:10.1002/biot.202000005.
- [32] Chen, Z.; Wan, L.; Yuan, Y.; Kuang, Y.; Xu, X.; Liao, T.; Liu, J.; Xu, Z.Q.; Jiang, B.; Li, C. PH/GSH-Dual-Sensitive Hollow Mesoporous Silica Nanoparticle-Based Drug Delivery System for Targeted Cancer Therapy. *ACS Biomater. Sci. Eng.* **2020**, *6*, 3375–3387, doi:10.1021/acsbmaterials.0c00073.
- [33] Cai, M.; Chen, G.; Qin, L.; Qu, C.; Dong, X.; Ni, J.; Yin, X. Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer. *Pharmaceutics* **2020**, *12*, doi:10.3390/pharmaceutics12030232.
- [34] Osterrieth, J.W.M.; Fairen-Jimenez, D. Metal–Organic Framework Composites for Theragnostics and Drug Delivery Applications. *Biotechnol. J.* **2021**, *16*, 1–14, doi:10.1002/biot.202000005.
- [35] Liu, X.; Liang, T.; Zhang, R.; Ding, Q.; Wu, S.; Li, C.; Lin, Y.; Ye, Y.; Zhong, Z.; Zhou, M. Iron-Based Metal-Organic Frameworks in Drug Delivery and Biomedicine. *ACS Appl. Mater. Interfaces* **2021**, *13*, 9643–9655, doi:10.1021/acsami.0c21486.
- [36] Bunzen, H. Chemical Stability of Metal-Organic Frameworks for Applications in Drug Delivery. *ChemNanoMat* **2021**, *7*, 998–1007, doi:10.1002/cnma.202100226.
- [37] Sun, J.; Huang, T.; Yin, Q.; Li, L.; Liu, T.F.; Huang, X.S.; Cao, R. Tuning the Structure and Hydrolysis Stability of Calcium Metal-Organic Frameworks through Integrating Carboxylic/Phosphinic/Phosphonic Groups in Building Blocks. *Cryst. Growth Des.* **2020**, *20*, 8021–8027, doi:10.1021/acs.cgd.0c01272.

- [38] Li, J.; Zhao, J.; Tan, T.; Liu, M.; Zeng, Z.; Zeng, Y.; Zhang, L.; Fu, C.; Chen, D.; Xie, T. Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review. *Int. J. Nanomedicine* **2020**, *15*, 2563–2582, doi:10.2147/IJN.S243223.
- [39] Kim, K.; Lee, S.; Jin, E.; Palanikumar, L.; Lee, J.H.; Kim, J.C.; Nam, J.S.; Jana, B.; Kwon, T.H.; Kwak, S.K.; et al. MOF × Biopolymer: Collaborative Combination of Metal-Organic Framework and Biopolymer for Advanced Anticancer Therapy. *ACS Appl. Mater. Interfaces* **2019**, *11*, 27512–27520, doi:10.1021/acsami.9b05736.
- [40] Rojas, S.; Horcajada, P. Metal – Organic Frameworks for the Removal of Emerging Organic Contaminants in Water. **2020**, doi:10.1021/acs.chemrev.9b00797.
- [41] Saeb, M.R.; Rabiee, N.; Mozafari, M.; Verpoort, F.; Voskressensky, L.G.; Luque, R. Metal – Organic Frameworks ( MOFs ) for Cancer Therapy. **2021**, 1–10.
- [42] Horcajada, P.; Chalati, T.; Serre, C.; Gillet, B.; Sebrie, C.; Baati, T.; Eubank, J.F.; Heurtaux, D.; Clayette, P.; Kreuz, C.; et al. Porous Metal-Organic-Framework Nanoscale Carriers as a Potential Platform for Drug Delivery and Imaging. *Nat. Mater.* **2010**, *9*, 172–178, doi:10.1038/nmat2608.
- [43] Leng, X.; Dong, X.; Wang, W.; Sai, N.; Yang, C.; You, L.; Huang, H.; Yin, X.; Ni, J. Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers. *Molecules* **2018**, *23*, doi:10.3390/molecules23102490.
- [44] Leng, X.; Dong, X.; Wang, W.; Sai, N.; Yang, C.; You, L.; Huang, H.; Yin, X.; Ni, J. Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers. *Molecules* **2018**, *23*, 1–13, doi:10.3390/molecules23102490.
- [45] Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. *N. Engl. J. Med.* **2011**, *364*, 1817–1825, doi:10.1056/NEJMoa1011923.
- [46] Demir Duman, F.; Monaco, A.; Foulkes, R.; Becer, C.R.; Forgan, R.S. Glycopolymer-Functionalized MOF-808 Nanoparticles as a Cancer-Targeted Dual Drug Delivery System for Carboplatin and Floxuridine. *ACS Appl. Nano Mater.* **2022**, *5*, 13862–13873, doi:10.1021/acsanm.2c01632.
- [47] Bhatnagar, S.; Kumari, P.; Pattarabhiran, S.P.; Venuganti, V.V.K. Zein Microneedles for Localized Delivery of Chemotherapeutic Agents to Treat Breast Cancer: Drug Loading, Release Behavior, and Skin Permeation Studies. *AAPS PharmSciTech* **2018**, *19*, 1818–1826, doi:10.1208/s12249-018-1004-5.
- [48] Waghule, T.; Singhvi, G.; Kumar, S.; Monohar, M. Microneedles : A Smart Approach and Increasing Potential for Transdermal Drug Delivery System. *Biomed. Pharmacother.* **2019**, *109*, 1249–1258, doi:10.1016/j.biopha.2018.10.078.
- [49] Özsoy, M.; Atiroğlu, V.; Guney Eskiler, G.; Atiroğlu, A.; Deveci Ozkan, A.; Özacar, M. A Protein-Sulfosalicylic Acid/Boswellic Acids @metal–Organic Framework Nanocomposite as Anticancer Drug Delivery System. *Colloids Surfaces B Biointerfaces* **2021**, *204*, doi:10.1016/j.colsurfb.2021.111788.
- [50] He, S.; Wu, L.; Li, X.; Sun, H.; Xiong, T.; Liu, J. Metal-Organic Frameworks for Advanced Drug Delivery. **2021**, *11*, doi:10.1016/j.apsb.2021.03.019.

- [51] Homayun, B.; Lin, X.; Choi, H.J. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. *Pharmaceutics* **2019**, *11*, doi:10.3390/pharmaceutics11030129.
- [52] Chen, D.; Yang, D.; Dougherty, C.A.; Lu, W.; Wu, H.; He, X.; Cai, T.; Van Dort, M.E.; Ross, B.D.; Hong, H. In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials. *ACS Nano* **2017**, *11*, 4315–4327, doi:10.1021/acsnano.7b01530.
- [53] Tibbetts, I.; Kostakis, G.E. Recent Bio-Advances in Metal-Organic Frameworks. **2020**, 1–32.
- [54] Li, C.; Wang, J.; Wang, Y.; Gao, H.; Wei, G.; Huang, Y.; Yu, H.; Gan, Y. Recent Progress in Drug Delivery. *Acta Pharm. Sin. B* **2019**, *9*, 1145–1162, doi:10.1016/j.apsb.2019.08.003.
- [55] Yang, W.; Veroniaina, H.; Qi, X.; Chen, P.; Li, F.; Ke, P.C. Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose. *Adv. Ther.* **2020**, *3*, 1900102, doi:10.1002/adtp.201900102.
- [56] He, S.; Wu, L.; Li, X.; Sun, H.; Xiong, T.; Liu, J.; Huang, C.; Xu, H.; Sun, H.; Chen, W.; et al. Metal-Organic Frameworks for Advanced Drug Delivery. *Acta Pharm. Sin. B* **2021**, *11*, 2362–2395, doi:10.1016/j.apsb.2021.03.019.
- [57] Li, X.; Porcino, M.; Qiu, J.; Constantin, D.; Martineau-Corcos, C.; Gref, R. Doxorubicin-Loaded Metal-Organic Frameworks Nanoparticles with Engineered Cyclodextrin Coatings: Insights on Drug Location by Solid State Nmr Spectroscopy. *Nanomaterials* **2021**, *11*, doi:10.3390/nano11040945.
- [58] Iranpour, S.; Bahrami, A.R.; Sh. Saljooghi, A.; Matin, M.M. Application of Smart Nanoparticles as a Potential Platform for Effective Colorectal Cancer Therapy. *Coord. Chem. Rev.* **2021**, *442*, 213949, doi:10.1016/j.ccr.2021.213949.
- [59] Li, X.; Lachmanski, L.; Safi, S.; Sene, S.; Serre, C.; Grenèche, J.M.; Zhang, J.; Gref, R. New Insights into the Degradation Mechanism of Metal-Organic Frameworks Drug Carriers. *Sci. Rep.* **2017**, *7*, 1–11, doi:10.1038/s41598-017-13323-1.
- [60] Awasthi, G.; Shivgotra, S.; Nikhar, S.; Sundarrajan, S.; Ramakrishna, S.; Kumar, P. Progressive Trends on the Biomedical Applications of Metal Organic Frameworks. *Polymers (Basel)*. **2022**, *14*, 1–29, doi:10.3390/polym14214710.
- [61] Mocniak, K.A.; Kubajewska, I.; Spillane, D.E.M.; Williams, G.R.; Morris, R.E. Incorporation of Cisplatin into the Metal-Organic Frameworks UiO66-NH<sub>2</sub> and UiO66-Encapsulation vs. Conjugation. *RSC Adv.* **2015**, *5*, 83648–83656, doi:10.1039/c5ra14011k.
- [62] Filippousi, M.; Turner, S.; Leus, K.; Sifaka, P.I.; Tseligka, E.D.; Vandichel, M.; Nanaki, S.G.; Vizirianakis, I.S.; Bikiaris, D.N.; Van Der Voort, P.; et al. Biocompatible Zr-Based Nanoscale MOFs Coated with Modified Poly(ε-Caprolactone) as Anticancer Drug Carriers. *Int. J. Pharm.* **2016**, *509*, 208–218, doi:10.1016/j.ijpharm.2016.05.048.
- [63] Sun, R.W.Y.; Zhang, M.; Li, D.; Li, M.; Wong, A.S.T. Enhanced Anti-Cancer Activities of a Gold(III) Pyrrolidinedithiocarbamate Complex Incorporated in a Biodegradable Metal-Organic Framework. *J. Inorg. Biochem.* **2016**, *163*, 1–7, doi:10.1016/j.jinorgbio.2016.06.020.
- [64] Taheri, M.; Bernardo, I. Di; Lowe, A.; Nisbet, D.R.; Tsuzuki, T. Green Full Conversion

- of ZnO Nanopowders to Well-Dispersed Zeolitic Imidazolate Framework-8 (ZIF-8) Nanopowders via a Stoichiometric Mechanochemical Reaction for Fast Dye Adsorption. *Cryst. Growth Des.* **2020**, *20*, 2761–2773, doi:10.1021/acs.cgd.0c00129.
- [65] Fantham, M.; Mishra, A.; Silvestre-albero, J.; Haddad, S.; Aba, I.; Osterrieth, J.W.M.; Schierle, G.S.K.; Kaminski, C.F.; Forgan, R.S.; Fairen-jimenez, D. Design of a Functionalized Metal – Organic Framework System for Enhanced Targeted Delivery to Mitochondria. **2020**, doi:10.1021/jacs.0c00188.
- [66] Bůžek, D.; Adamec, S.; Lang, K.; Demel, J. Metal-Organic Frameworks: Vs. Buffers: Case Study of UiO-66 Stability. *Inorg. Chem. Front.* **2021**, *8*, 720–734, doi:10.1039/d0qi00973c.
- [67] Rezaei, M.; Abbasi, A.; Varshochian, R.; Dinarvand, R.; Jeddi-Tehrani, M. NanoMIL-100(Fe) Containing Docetaxel for Breast Cancer Therapy. *Artif. Cells, Nanomedicine Biotechnol.* **2018**, *46*, 1390–1401, doi:10.1080/21691401.2017.1369425.
- [68] Zhou, J.; Tian, G.; Zeng, L.; Song, X.; Bian, X.W. Nanoscaled Metal-Organic Frameworks for Biosensing, Imaging, and Cancer Therapy. *Adv. Healthc. Mater.* **2018**, *7*, 1–21, doi:10.1002/adhm.201800022.
- [69] Li, L.; Han, S.; Zhao, S.; Li, X.; Liu, B.; Liu, Y. Chitosan Modified Metal-Organic Frameworks as a Promising Carrier for Oral Drug Delivery. *RSC Adv.* **2020**, *10*, 45130–45138, doi:10.1039/d0ra08459j.
- [70] Sharma, S.; Mittal, Di.; Verma, A.K.; Roy, I. Copper-Gallic Acid Nanoscale Metal-Organic Framework for Combined Drug Delivery and Photodynamic Therapy. *ACS Appl. Bio Mater.* **2019**, *2*, 2092–2101, doi:10.1021/acsabm.9b00116.
- [71] Wu, J.; Ouyang, D.; He, Y.; Su, H.; Yang, B.; Li, J.; Sun, Q.; Lin, Z.; Cai, Z. Synergistic Effect of Metal – Organic Framework / Gallic Acid in Enhanced Laser Desorption / Ionization Mass Spectrometry. **2019**, doi:10.1021/acsami.9b11100.
- [72] Chen, J.; Liu, J.; Hu, Y.; Tian, Z.; Zhu, Y. Metal-Organic Framework-Coated Magnetite Nanoparticles for Synergistic Magnetic Hyperthermia and Chemotherapy with PH-Triggered Drug Release. *Sci. Technol. Adv. Mater.* **2019**, *20*, 1043–1054, doi:10.1080/14686996.2019.1682467.
- [73] Bikiaris, N.D.; Ainali, N.M.; Christodoulou, E.; Kostoglou, M.; Kehagias, T.; Papasouli, E.; Koukaras, E.N.; Nanaki, S.G. Dissolution Enhancement and Controlled Release of Paclitaxel Drug via a Hybrid Nanocarrier Based on Mpeg-Pcl Amphiphilic Copolymer and Fe-Btc Porous Metal-Organic Framework. *Nanomaterials* **2020**, *10*, 1–30, doi:10.3390/nano10122490.
- [74] Liu, J.; Tang, M.; Zhou, Y.; Long, Y.; Cheng, Y.; Zheng, H. A Siramesine-Loaded Metal Organic Framework NanoplatforM for Overcoming Multidrug Resistance with Efficient Cancer Cell Targeting. *RSC Adv.* **2020**, *10*, 6919–6926, doi:10.1039/c9ra09923a.
- [75] Hou, L.; Liu, Y.; Liu, W.; Balash, M.; Zhang, H.; Zhang, Y.; Zhang, H.; Zhang, Z. In Situ Triggering Antitumor Efficacy of Alcohol-Abuse Drug Disulfiram through Cu-Based Metal-Organic Framework Nanoparticles. *Acta Pharm. Sin. B* **2021**, *11*, 2016–2030, doi:10.1016/j.apsb.2021.01.013.
- [76] Ahmadijokani, F.; Tajahmadi, S.; Rezakazemi, M.; Sehat, A.A.; Molavi, H.; Aminabhavi, T.M.; Arjmand, M. Aluminum-Based Metal-Organic Frameworks for Adsorptive Removal of Anti-Cancer (Methotrexate) Drug from Aqueous Solutions. *J. Environ. Manage.* **2021**, *277*, 111448, doi:10.1016/j.jenvman.2020.111448.

- [77] Abazari, R.; Reza Mahjoub, A.; Slawin, A.M.Z.; Carpenter-Warren, C.L. Morphology- and Size-Controlled Synthesis of a Metal-Organic Framework under Ultrasound Irradiation: An Efficient Carrier for PH Responsive Release of Anti-Cancer Drugs and Their Applicability for Adsorption of Amoxicillin from Aqueous Solution. *Ultrason. Sonochem.* **2018**, *42*, 594–608, doi:10.1016/j.ultsonch.2017.12.032.
- [78] Imanipoor, J.; Mohammadi, M.; Dinari, M.; Ehsani, M.R. Adsorption and Desorption of Amoxicillin Antibiotic from Water Matrices Using an Effective and Recyclable MIL-53(Al) Metal-Organic Framework Adsorbent. *J. Chem. Eng. Data* **2021**, *66*, 389–403, doi:10.1021/acs.jced.0c00736.
- [79] Proenza, Y.G.; Longo, R.L. Simulation of the Adsorption and Release of Large Drugs by ZIF-8. *J. Chem. Inf. Model.* **2020**, *60*, 644–652, doi:10.1021/acs.jcim.9b00893.
- [80] Bhadra, B.N.; Ahmed, I.; Kim, S.; Jhung, S.H. Adsorptive Removal of Ibuprofen and Diclofenac from Water Using Metal-Organic Framework-Derived Porous Carbon. *Chem. Eng. J.* **2017**, *314*, 50–58, doi:10.1016/j.cej.2016.12.127.
- [81] Ni, W.; Xiao, X.; Li, Y.; Li, L.; Xue, J.; Gao, Y.; Ling, F. DETA Impregnated Attapulgite Hybrid ZIF-8 Composite as an Adsorbent for the Adsorption of Aspirin and Ibuprofen in Aqueous Solution. *New J. Chem.* **2021**, *45*, 5637–5644, doi:10.1039/d0nj05743f.
- [82] Wu, G.; Ma, J.; Li, S.; Guan, J.; Jiang, B.; Wang, L.; Li, J.; Wang, X.; Chen, L. Magnetic Copper-Based Metal Organic Framework as an Effective and Recyclable Adsorbent for Removal of Two Fluoroquinolone Antibiotics from Aqueous Solutions. *J. Colloid Interface Sci.* **2018**, *528*, 360–371, doi:10.1016/j.jcis.2018.05.105.
- [83] Taghvimi, A.; Tabrizi, A.B.; Dastmalchi, S.; Javadzadeh, Y. Metal Organic Framework Based Carbon Porous as an Efficient Dispersive Solid Phase Extraction Adsorbent for Analysis of Methamphetamine from Urine Matrix. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2019**, *1109*, 149–154, doi:10.1016/j.jchromb.2019.02.005.
- [84] Baheri, T.; Yamini, Y.; Shamsayei, M.; Tabibpour, M. Application of HKUST-1 Metal-Organic Framework as Coating for Headspace Solid-Phase Microextraction of Some Addictive Drugs. *J. Sep. Sci.* **2021**, *44*, 2814–2823, doi:10.1002/jssc.202100070.
- [85] Cao, S.; Tang, T.; Xi, C.; Chen, Z. Fabricating Magnetic GO/ZIF-8 Nanocomposite for Amphetamine Adsorption from Water: Capability and Mechanism. *Chem. Eng. J.* **2021**, *422*, 130096, doi:10.1016/j.cej.2021.130096.
- [86] Ongari, D.; Liu, Y.M.; Smit, B. Can Metal-Organic Frameworks Be Used for Cannabis Breathalyzers? *ACS Appl. Mater. Interfaces* **2019**, *11*, 34777–34786, doi:10.1021/acsami.9b13357.
- [87] Yang, H.; Li, L.; Cao, H.; Zhang, Z.; Zhao, T.; Hao, Y.; Wang, M. Silica Supported Metal Organic Framework 808 Composites as Adsorbent for Solid-Phase Extraction of Benzodiazepines in Urine Sample. *Microchem. J.* **2020**, *157*, doi:10.1016/j.microc.2020.105062.
- [88] Zhang, Y.; Yan, B. A Novel Cucurbit[7]Uril Anchored Bis-Functionalized Metal-Organic Framework Hybrid and Its Potential Use in Fluorescent Analysis of Illegal Stimulants in Saliva. *Sensors Actuators, B Chem.* **2020**, *324*, 128656, doi:10.1016/j.snb.2020.128656.